The Diabetes Centre provides comprehensive medical care for diabetes and its related complications. This includes specialized medical services under one roof, catering to a range of diabetes treatment needs.

The Diabetes Centre

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 is the #1 rated insulin pump and the #1 rated automated insulin delivery system [dQ&A US Patient Panel Q2 2023 (Apr-Jun 2023)].

For more information, visit tandemdiabetes.com.

SAFETY INFORMATION 
Please note that this account is not intended to be used for product support or medical advice. If you are having a medical emergency, please dial 911. If you are having an issue with one of our products and need immediate assistance, please call our 24 hour customer support team at 877-801-6901 and press 1 twice. 

RX ONLY. BOXED WARNING: Should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. For boxed warning and safety information, see tandemdiabetes.com/safetyinfo.


Tandem Diabetes Care

Jordan Pinsker, MD, Chief Medical Officer for Tandem Diabetes Care, shares the key findings of the Control-IQ Observational (CLIO) study, the largest observational study of Control-IQ advanced hybrid closed-loop technology to date. ​
​
RX ONLY. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. Safety info: https://lnkd.in/d3SmUSb ​

Compatibility update: We are thrilled to announce that the mobile bolus feature on the t:connect mobile app is now available on Google devices of the Pixel 4 family and later, and Samsung 24 devices! (Users received an in-app notification earlier that mobile bolus is compatible with Android OS 14.) Find a full list of mobile app compatibility here: https://bit.ly/3SH0Rpw

At Tandem, we promote diversity and work-life balance through Inclusion Communities (otherwise known as Employee Resource Groups).  As part of the Diversity, Equity, and Inclusion (DEI) initiatives at Tandem, Inclusion Communities provide a welcoming and supportive environment where employees can meet, encourage each other, and grow where they feel the most comfortable. 

Tandem is excited to announce a new Inclusion Community coming soon, Black Employees at Tandem (BET). Meet the three founders of BET and hear what brought them together to help Tandem employees love where they work even more. Read more: https://lnkd.in/exqGskr2

The t:slim X2 insulin pump is the first to connect with Freestyle Libre 2 Plus, Dexcom G6, and Dexcom G7. We’ve been integrating with industry-leading CGMs for more than 10 years. Find out more: https://bit.ly/3SJkZHD

Safety info: https://bit.ly/2OKAQsw

Excitement is building for the Advanced Technologies & Treatments for Diabetes (ATTD) annual meeting in Florence, Italy. Mark your calendars because we're bringing innovation to booth #76, and you won't want to miss it!

🗓️ Save the Dates: 6-9 March 2024
📍 Booth #76
⌚ Exclusive Booth Hours (CEST):
Wed., 6 March: 18:30-20:00 
Thu., 7 March: 09:30-17:00
Fri., 8 March: 10:00-17:30
Sat., 9 March: 10:30-15:30

🎙️ Join us for our captivating oral presentations: https://lnkd.in/ejf4yb4A 
1. “High Satisfaction with Control-IQ 1.5 and Lyumjev Insulin in Children, Adolescents and Adults with Type 1 Diabetes” with Carol Levy, MD, CDCES, Professor of Medicine and Obstetrics, Director Mount Sinai Diabetes Center, Icahn School of Medicine at Mount Sinai. 
2. "Real-world Improvements in Glycemic Control and Patient-Reported Outcomes One Year After Initiation of Tandem Control-IQ in People with Type 1 Diabetes" with Jolien De Meulemeester, University Hospitals Leuven - KU Leuven, Leuven.
3. "What Happens when People Don’t Bolus for a Week with t:slim X2 Insulin Pump with Control-IQ Technology?” with Laurel Messer, PhD, MPH, RN, CDCES.

Register today at https://lnkd.in/d2TvbdMg and stop by booth #76 to uncover the brilliance of the t:slim X2 insulin pump (the #1 rated AID system [dQ&A US Patient Panel Q3 2023 {July-Sept. 2023}]), marvel at the Tandem Mobi (the world's smallest, durable AID system [As of Feb., 2024. Data on file, Tandem Diabetes Care]), and dive into the revolutionary Dexcom G7 CGM integration on a global scale. 

👋 See you soon! 

RX ONLY. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 25 kg. Safety info: https://lnkd.in/d3SmUSb   

#ATTD2024 #TandemDiabetes

Metric
Company Name	The Diabetes Centre
Symbol
MSH ID	ORG:THEDIABETESCENTRE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Services
Country	PK
Stage
Employee Count
Website	thediabetescentre.org
LinkedIn	the-diabetes-centre
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:TANDEMDIABETES

Tandem Diabetes Care, Inc.

Last Close

30.74

22/11 21:00

Market Cap

2.86B

Beta: -

Volume Today

1.18M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue